title: Personalized oncology in interventional radiology.
abstract: As personalized medicine becomes more applicable to oncologic practice, image-guided biopsies will be integral for enabling predictive and pharmacodynamic molecular pathology. Interventional radiology has a key role in defining patient-specific management. Advances in diagnostic techniques, genomics, and proteomics enable a window into subcellular mechanisms driving hyperproliferation, metastatic capabilities, and tumor angiogenesis. A new era of personalized medicine has evolved whereby clinical decisions are adjusted according to a patient's molecular profile. Several mutations and key markers already have been introduced into standard oncologic practice. A broader understanding of personalized oncology will help interventionalists play a greater role in therapy selection and discovery.
authors.affiliation: Radiology and Imaging Sciences, National Institutes of Health, Rockville Pike, Bethesda, MD 20892, USA. naj@mail.nih.gov
authors.forename: Nadine
authors.initials: N
authors.lastname: Abi-Jaoudeh
authors.forename: Austin G
authors.initials: AG
authors.lastname: Duffy
authors.forename: Tim F
authors.initials: TF
authors.lastname: Greten
authors.forename: Elise C
authors.initials: EC
authors.lastname: Kohn
authors.forename: Timothy W I
authors.initials: TW
authors.lastname: Clark
authors.forename: Bradford J
authors.initials: BJ
authors.lastname: Wood
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism; D020022:Genetic Predisposition to Disease; D005820:Genetic Testing; D023281:Genomics; D006801:Humans; D061705:Image-Guided Biopsy; D008495:Medical Oncology / Q000379:methods*; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D018579:Patient Selection; D010641:Phenotype; D057285:Precision Medicine; D011237:Predictive Value of Tests; D015641:Radiography, Interventional; D015398:Signal Transduction / Q000187:drug effects / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor
keywords: ALK; ATP; BCR-ABL; BRAF; CD-20; CML; CRC; EGFR; EML4; FDA; Food and Drug Administration; HCC; HER-2; KRAS; Kirsten rat sarcoma viral oncogene; NSCLC; PDGFR; SMKI; VEGF; VEGFR2; adenosine triphosphate; analplastic lymphoma factor; breakpoint cluster region/the Abelson tyrosine; c-KIT; chronic myelogenous leukemia; clusters of differentiation-20 (antigen of B-cells); colorectal carcinoma; echinoderm microtubule-associated protein-like 4; epidermal growth factor receptor; hepatocellular carcinoma; human epidermal growth factor receptor-2; mAb; mTOR; mammalian target of rapamycin; monoclonal antibody; non–small cell lung carcinoma; platelet-derived growth factor receptor; small molecule kinase inhibitor; tyrosine-protein kinase kit or mast/stem cell growth factor receptor; v-raf murine sarcoma viral oncogene; vascular endothelial growth factor; vascular endothelial growth factor receptor-2